Scientists investigate the long-term effect of hormonal therapy in breast cancer women. Recently, scientists examined the effect of hormonal therapy in hormone-sensitive breast cancer. The study results are published in the journal JAMA Oncology.
The researchers found that the therapy showed a protective effect against distant metastatic cancer and a long-term effect in women diagnosed with Luminal A cancer.
Estrogen receptor-positive (hormone sensitive) breast cancer is the most common type of breast cancer diagnosed today. Researchers said that women with this form of breast cancer are at long-term risk of developing a distant metastatic spread of the disease and mortality from breast cancer.
The researchers at Karolinska Institutet in Sweden looked at the long-term effect of hormonal therapy in women with estrogen receptor-positive breast cancer. 336 women were diagnosed with Luminal A breast cancer subtype, while 126 women had received Luminal B subtype diagnosis.
Their analysis found that there was a small but prolonged risk increase for metastatic cancer in women with Luminal A breast cancer, while the high risk for metastatic breast cancer in people with Luminal B subtype. Tamoxifen therapy reduced both cancers’ risk.
“Our conclusion is that tamoxifen treatment is beneficial for both groups of patients, but that it has a long-term protective effect for patients with Luminal A breast cancer,” says Dr. Linda Lindström, who coordinated the study. “Patients with Luminal B breast cancer should also be offered hormonal therapy, and our results show a reduced risk of metastatic disease during the first years when the risk is the highest for these patients,” Linda added.